Our DNA

Born of the determination to bring concrete solutions to patients with no therapeutic option, Laboratoires KÔL is built on two pillars: recognised regulatory expertise in access to treatments for rare diseases, and long-standing expertise in ophthalmology.

KÔL takes its name from kôhl, the first eye-care product, used in Ancient Egypt and considered the very first eye treatment: a nod to our roots in ophthalmology.

Since it was founded in 2020, KÔL has been committed to meeting unmet medical needs by enabling rapid access to innovative medicines. This approach has already made it possible to treat more than 15,000 patients with rare eye diseases.

Driven by the energy and agility of a start-up, KÔL has grown quickly to structure and broaden its scope. Today, KÔL is strengthening its R&D and pharmaceutical development activities, focusing on areas where medical needs remain insufficiently met. The laboratory develops targeted therapeutic solutions, placing the patient at the heart of every innovation.

Our ambition: to provide concrete answers where treatment options remain limited.